Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4X0SJ)

Drug Name
2-(4,5-dihydro-1H-imidazol-2-yl)quinoline Drug Info
Synonyms
BU 224; 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline; CHEMBL13698; 2-(4,5-Dihydroimidaz-2-yl)-Quinoline; BU-224; NCGC00015130-01; Tocris-0725; Lopac-B-154; AC1L1DPZ; Lopac0_000167; SCHEMBL1526637; CHEBI:92967; CTK5J7405; ZINC2565858; BDBM50240365; CCG-204262; NCGC00024750-02; NCGC00015130-02; NCGC00024750-01; NCGC00015130-03; NCGC00015130-04; 2-(4,5-Dihydro-1H-imidazol-2-yl)-quinoline
Cross-matching ID
PubChem CID
2457
ChEBI ID
CHEMBL13698
CAS Number
CAS 187173-05-3
TTD Drug ID
D0A4AB

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.17 0.00e+0 93/133 (69.92%) COX7B;NDUFA5;NDUFA4;...
Ribosome 2.03 0.00e+0 113/158 (71.52%) RPS5;RSL24D1;MRPL12;...
Staphylococcus aureus infection 1.94 1.30e-2 72/95 (75.79%) CFH;KRT17;DEFB1;...
Thermogenesis 1.93 9.73e-3 173/232 (74.57%) COX7B;NDUFA5;NDUFA4;...
Allograft rejection 1.90 7.79e-3 32/38 (84.21%) CD40;HLA-DRB1;IFNG;...
Viral protein interaction with cytokine and cytokine re... 1.89 6.49e-3 84/100 (84%) TNFSF10;CCL8;IL18;...
Systemic lupus erythematosus 1.83 1.39e-2 45/135 (33.33%) CD40;HLA-DRB1;C1QA;...
Asthma 1.82 1.22e-2 25/31 (80.65%) CD40;HLA-DRB1;CCL11;...
Proteasome 1.80 1.19e-2 44/46 (95.65%) PSMA2;IFNG;PSMA4;...
Prion disease 1.74 2.24e-2 209/273 (76.56%) COX7B;CAV1;CAV2;...
Non-alcoholic fatty liver disease 1.73 2.12e-2 126/155 (81.29%) COX7B;NDUFA5;NDUFA4;...
Diabetic cardiomyopathy 1.70 2.76e-2 162/203 (79.8%) COX7B;NDUFA5;NDUFA4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colon carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 TP53(-/-) CVCL_HD97 Homo sapiens 0.04uM - 10uM 24H
HCT 116 CVCL_0291 Homo sapiens 0.04uM - 10uM 24H
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 (Parent) CVCL_0291 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 6H, 24H